ATE535612T1 - Toxizitätsscreeningverfahren - Google Patents

Toxizitätsscreeningverfahren

Info

Publication number
ATE535612T1
ATE535612T1 AT07752400T AT07752400T ATE535612T1 AT E535612 T1 ATE535612 T1 AT E535612T1 AT 07752400 T AT07752400 T AT 07752400T AT 07752400 T AT07752400 T AT 07752400T AT E535612 T1 ATE535612 T1 AT E535612T1
Authority
AT
Austria
Prior art keywords
toxicity
concentration
determining
cell type
present
Prior art date
Application number
AT07752400T
Other languages
English (en)
Inventor
James Mckim
Original Assignee
Ceetox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceetox Inc filed Critical Ceetox Inc
Application granted granted Critical
Publication of ATE535612T1 publication Critical patent/ATE535612T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061Muscle cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067Liver cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT07752400T 2006-03-06 2007-03-06 Toxizitätsscreeningverfahren ATE535612T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77966006P 2006-03-06 2006-03-06
US74359906P 2006-03-21 2006-03-21
PCT/US2007/005696 WO2007103374A2 (en) 2006-03-06 2007-03-06 Toxicity screening methods

Publications (1)

Publication Number Publication Date
ATE535612T1 true ATE535612T1 (de) 2011-12-15

Family

ID=38475502

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07752400T ATE535612T1 (de) 2006-03-06 2007-03-06 Toxizitätsscreeningverfahren

Country Status (4)

Country Link
US (3) US7615361B2 (de)
EP (2) EP2287327B1 (de)
AT (1) ATE535612T1 (de)
WO (1) WO2007103374A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2027465A2 (de) 2006-05-17 2009-02-25 Cellumen, Inc. Verfahren für automatisierte gewebeanalyse
WO2009061832A1 (en) * 2007-11-05 2009-05-14 Kci Licensing Inc. Identification of tissue for debridement
WO2009153131A1 (en) * 2008-05-28 2009-12-23 Basf Se Means and methods for assessing liver enzyme induction
EP2294412A1 (de) * 2008-06-04 2011-03-16 Ceetox Inc. Verfahren zur vorhersage der hautsensibilisierungswirkung von verbindungen
WO2010094694A1 (en) * 2009-02-23 2010-08-26 F. Hoffmann-La Roche Ag Assays to predict cardiotoxicity
WO2010141954A1 (en) * 2009-06-06 2010-12-09 Ceetox, Inc. Method for predicting respiratory toxicity of compounds
CA2776383C (en) * 2009-10-06 2019-04-30 Wisconsin Alumni Research Foundation Metabolic biomarkers of drug-induced cardiotoxicity
US20110212461A1 (en) * 2010-02-26 2011-09-01 Hans Marcus Ludwig Bitter Prediction of cardiotoxicity
US20110212480A1 (en) * 2010-02-26 2011-09-01 Kyle Louis Kolaja Use of primary human cardiomyocytes
US20120179381A1 (en) * 2010-06-17 2012-07-12 Mckim James M Toxicity screening methods
WO2012016150A2 (en) * 2010-07-29 2012-02-02 The Board Of Trustees Of The University Of Illinois Methods for predicting risk of stroke
US10018631B2 (en) 2011-03-17 2018-07-10 Cernostics, Inc. Systems and compositions for diagnosing Barrett's esophagus and methods of using the same
EP2574924A1 (de) 2011-09-28 2013-04-03 Merck Patent GmbH Verfahren zur Bestimmung des Status von Zellen
US10852296B2 (en) * 2011-12-27 2020-12-01 BiOMICom Incorporated Micro-sampling for cell, tissue, and micro-organism monitoring
WO2013116307A1 (en) 2012-01-30 2013-08-08 Mount Sinai School Of Medicine Method for programming differentiated cells into hematopoietic stem cells
EA201492178A1 (ru) 2012-05-22 2015-12-30 Берг Ллк Основанные на клетках перекрестные анализы для идентификации маркеров индуцированной лекарственными средствами токсичности
HK1212767A1 (zh) 2012-09-12 2016-06-17 Berg Llc 標誌物用於識別心臟毒性劑的用途
CA2995767A1 (en) * 2015-08-18 2017-02-23 Coyne Scientific, Llc Method of estimating the incidence of in vivo reactions to chemical or biological agents using in vitro experiments
CN106770693A (zh) * 2015-11-19 2017-05-31 中国药科大学 新型药物体外温孵、代谢物寻找、药物-药物相互作用预测快速筛选与分析整合策略
GB201700138D0 (en) 2017-01-05 2017-02-22 Senzagen Ab Analytical methods and arrays for use in the same
EP4185706A4 (de) * 2020-07-24 2024-09-11 The University Of Tulsa Synthese und verwendung von n-benzylsulfonamiden
CN115616134A (zh) * 2022-10-24 2023-01-17 南京理工大学 一种新污染物转化效应的评估系统
CN117169091B (zh) * 2023-07-28 2024-09-13 恩大细胞基因工程有限公司 一种细胞活性检测系统
US20250316343A1 (en) * 2024-03-08 2025-10-09 AxiomBio, Inc. Optimizing molecule toxicity by replacing target fragments with bioisosteres

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL62879A (en) 1981-05-15 1985-09-29 Chaya Moroz Monoclonal antibodies,clones producing them,preparation of such antibodies and clones and cytotoxic and immunoassay using such antibodies
US4532751B1 (en) 1984-04-16 1998-02-03 Mayer Oskar Foods Automatic sheet product line
GB9221664D0 (en) 1992-10-15 1992-11-25 Shiny Chemical Ind Co Limited Propylene glycol monomethyl ether propionate and the process for the preparation thereof
CA2189634A1 (en) 1994-05-06 1995-11-16 John J. Baldwin Combinatorial dihydrobenzopyran library
AU2553195A (en) 1994-05-23 1995-12-18 Arqule, Inc. Systematic modular production of aminimide- and oxazolone- based molecules having at least two structural diversity elements
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
WO1997049653A2 (en) 1996-06-24 1997-12-31 Irori Solid phase tyrphostin library linked to matrices with memories
US6558916B2 (en) * 1996-08-02 2003-05-06 Axiom Biotechnologies, Inc. Cell flow apparatus and method for real-time measurements of patient cellular responses
US5985268A (en) * 1997-09-15 1999-11-16 Lockheed Martin Energy Research Corp. Gamma-irradiated bacterial preparation having anti-tumor activity
US6998249B1 (en) * 1999-09-27 2006-02-14 Pharmacia & Upjohn Company Toxicity screening method

Also Published As

Publication number Publication date
EP1996718A4 (de) 2009-11-25
US7615361B2 (en) 2009-11-10
EP2287327A1 (de) 2011-02-23
WO2007103374A9 (en) 2009-01-15
EP1996718B1 (de) 2011-11-30
WO2007103374A2 (en) 2007-09-13
US20110008823A1 (en) 2011-01-13
EP1996718A2 (de) 2008-12-03
WO2007103374A3 (en) 2008-11-27
US20130252270A1 (en) 2013-09-26
EP2287327B1 (de) 2013-06-05
US20070218457A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
ATE535612T1 (de) Toxizitätsscreeningverfahren
DE602004030054D1 (de) Untersuchungsvorrichtung für biologische Proben und chemische Proben
ATE428929T1 (de) Reagens, ausstattung und verfahren zur probenanalyse
ATE438853T1 (de) Diagnostische testvorrichtung
NO339224B1 (no) Bedrede immunprøvemetoder
ATE527543T1 (de) Testvorrichtung zur schnelldiagnose
EP2340300A4 (de) Verfahren zur erkennung von analyten
GB0612649D0 (en) No title
EP2134724A4 (de) Reagentien zum nachweis von hypochloriger säure
ATE531820T1 (de) Gesundheitszustandstest
MX2009006159A (es) Elemento de prueba con referencia.
ATE471512T1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
WO2011021041A3 (en) Survival prognostic assay
ATE537271T1 (de) Toll-like-rezeptor-4-dysfunktion und biologische anwendungen davon
ATE370414T1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
MX2009010751A (es) Composiciones y metodos de deteccion.
DK2185939T3 (da) Engangsanalyseudstyr med mikroprocessor
DE602005014386D1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
FI20040255A7 (fi) Menetelmä pre-eklampsian riskin havaitsemiseksi
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
DE602004001994D1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
FR2894675B1 (fr) Distinction des meningites bacteriennes et virales